iNEURO

iNEURO was founded in 2014, with its headquarters located in Hangzhou. As a national high-tech enterprise, it focuses on the industrial transformation of China's indigenous brain science technology and is dedicated to exploring and serving the field of brain science. The founding team consists of a group of Ph.D. graduates from Zhejiang University and has attracted top professional technical talents from both within and outside China to join over the years. Collaborating closely with clinical institutions, the company has been deeply engaged in developing intelligent EEG (electroencephalogram) and artificial intelligence (AI) algorithms for diagnosing and treating brain diseases. It provides core products and services such as intelligent medical EEG solutions, ultra-fast lossless multimodal data encryption transmission, and AI diagnostic algorithms for brain diseases. Currently, the company’s business covers more than 20 provinces across China, successfully establishing 10 regional EEG reading centers that serve over 10 million grassroots patients. iNEURO's independently developed "iNeuro" EEG cloud system, AI algorithm screening tools, and multimodal brain science data platforms fill the market gap in China’s EEG monitoring systems. It has completed the design, development, and production of a series of products including medical video/dynamic EEG machines and portable VEEG video EEG machines, obtaining certifications such as NMPA Class II medical device registration, production license, EU CE certification, and Level 3 Information System Security Protection certification. As of June 2023, iNEURO has led and participated in six national-level scientific research projects, ten key provincial/ministerial-level projects, published 20 SCI papers, obtained 17 national patents, and registered 41 software copyrights. Exploring brain science and extending the boundaries of healthcare, iNEURO will continue to collaborate with government bodies, clinical medical institutions, and expert teams in medical research. It is committed to deepening research and application of EEG algorithm recognition in neurological and psychiatric diseases such as depression, cognitive disorders, and especially Alzheimer's Disease (AD). Additionally, it aims to strengthen cooperation in areas like brain health education, risk screening, disease intervention, brain health center construction, and brain health city initiatives, contributing to the realization of the "Healthy China 2030" strategic goals and the vision of "brain health for all."